Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer

	About this book
	AHRQ Evidence Reports, Numbers 61 - 119
	78. Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer
	Acknowledgments
	Preface
	Structured Abstract
	Summary
	Chapter 1. Introduction
	Chapter 2. Methodology
	Chapter 3. Results
	Chapter 4. Conclusions
	Chapter 5. Future Research
	Tables
	Figures
	References
	Appendix A: CANCER - Best-Case Series Abstraction Form
	Appendix B: Case Report Form
	Appendix C IAT Patient Questionnaire IAT Next-of-Kin Questionnaire Naltrexone Patient Questionnaire Naltrexone Next-of-Kin Questionnaire
	Appendix D Letters to Patients Including (3) Consent Forms
	Appendix E: Additional Cases Reviewed

78. Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer

Prepared for:

Agency for Healthcare Research and Quality

U.S. Department of Health and Human Services

www.ahrq.gov

Contract No: 290-97-0001

Prepared by:

Southern California-RAND Evidence-based Practice Center, Santa Monica, CA

EPC Director

Paul Shekelle, M.D., Ph.D.

Principal Investigators

Ian Coulter, Ph.D.

Mary Hardy, M.D.

EPC Director/Statistician

Sally C. Morton, Ph.D.

Expert Reviewers

Joya T. Favreau, M.D.

James Gagne, M.D.

S. Adelaide Coulter, R.N.

Jay Udani, M.D.

Elizabeth A. Roth, M.A.

Lara K. Jungvig, B.A.

Sydne Newberry, Ph.D.

Leigh Rohr

Louis R. Ramirez, B.A.

AHRQ Publication No. 03-E030

April 2003

ISBN: 1-58763-082-6

ISSN: 1530-4396

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakerspatients and clinicians, health system leaders, and policymakersmake more informed decisions and improve the quality of health care services.

Suggested Citation:

Coulter I, Hardy M, Shekelle P, et al. Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer. Evidence Report/Technology Assessment No. 78 (Prepared by Southern California-RAND Evidence-based Practice Center under Contract No 290-97-0001). AHRQ Publication No. 03-E030. Rockville, MD: Agency for Healthcare Research and Quality. April 2003.